April 18, 2023
Drug companies Merck and Glenmark Pharmaceuticals have settled a group of direct purchasers’ claims that they gouged drug buyers via an anti-competitive 2010 pay-for-delay patent settlement, leaving one fewer group of plaintiffs just as jury selection in a highly anticipated trial is set to kick off, according to court records.
The multidistrict litigation trial in Norfolk, Virginia, is expected to yield an extremely rare jury verdict in the pay-for-delay case, one of fewer than three in the decade since the U.S. Supreme Court’s landmark Actavis ruling in 2013.
That verdict will happen with a smaller group of plaintiffs after the settlement noted on the court docket midday Tuesday. The terms have not been made public.
. . .
The plaintiffs are represented by Glasser & Glasser PLC, Hagens Berman Sobol Shapiro LLP, Radice Law Firm PC, Hilliard Shadowen LLP, Sperling & Slater PC, Kessler Topaz Meltzer & Check LLP, Roberts Law Firm PA, Cohen Milstein Sellers & Toll PLLC, Miller Shah LLP, Nussbaum Law Group PC, Faruqi & Faruqi LLP, Berger Montague, Taus Cebulash & Landau LLP, Furniss Davis Rashkind & Saunders PC, Motley Rice LLC, Miller Law LLC, Wolcott Rivers Gates PC, Kenny Nachwalter PA, and Hangley Aronchick Segal Pudlin & Schiller.
Read the complete story on Law360 (subscription required).